Illexcor Therapeutics, a Richmond, VA-based biopharmaceutical company developing new oral therapies for sickle cell disease (SCD), received an investment from Zynext Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to expand operations and its development efforts.
Led by CEO Andrew Fleischman, Illexcor Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative oral therapies for sickle cell disease. Their lead asset is a drug designed to directly target the root cause of SCD, offering the potential for significant disease-modifying clinical benefits.
Commenting on the news, Andrew Fleischman said: “We are excited to partner with Zynext Ventures to advance our lead drug ILX002 into clinical trials later this year. We are hopeful that ILX002 will be a transformative treatment not only for SCD patients in the U.S. but also for millions around the globe. Zynext Ventures and Zydus Lifesciences are in a strategic position to help us achieve these goals.”
FinSMEs
12/03/2025